{
    "root": "80a1ff59-c8de-4141-b778-f1fc695fd58f",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Testosterone",
    "value": "20200601",
    "ingredients": [
        {
            "name": "TESTOSTERONE",
            "code": "3XMK78S47O"
        },
        {
            "name": "BUTYLATED HYDROXYTOLUENE",
            "code": "1P9D0Z171K"
        },
        {
            "name": "CARBOMER COPOLYMER TYPE C (ALLYL PENTAERYTHRITOL CROSSLINKED)",
            "code": "1N11AG4X4L"
        },
        {
            "name": "ALCOHOL",
            "code": "3K9958V90M"
        },
        {
            "name": "ISOPROPYL ALCOHOL",
            "code": "ND2M416302"
        },
        {
            "name": "OLEIC ACID",
            "code": "2UMI9U37CP"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "TROLAMINE",
            "code": "9O3K93S3TK"
        }
    ],
    "indications": "testosterone topical gel indicated replacement therapy males conditions associated deficiency absence endogenous testosterone : primary hypogonadism ( congenital acquired ) \u2013 testicular failure due conditions cryptorchidism , bilateral torsion , orchitis , vanishing testis syndrome , orchiectomy , klinefelter \u2019 syndrome , chemotherapy , toxic damage alcohol , heavy metals . men usually low serum testosterone concentrations gonadotropins ( follicle stimulating hormone [ fsh ] luteinizing hormone [ lh ] ) normal range . hypogonadotropic hypogonadism ( congenital acquired ) \u2013 gonadotropin luteinizing hormone-releasing hormone ( lhrh ) deficiency pituitary-hypothalamic injury tumors , trauma , radiation . men low serum testosterone concentrations gonadotropins normal low range . limitations safety efficacy testosterone topical gel men \u201c age-related hypogonadism \u201d ( also referred \u201c late-onset hypogonadism \u201d ) established . safety efficacy testosterone topical gel males less 18 years old established [ ( 8.4 ) ] .",
    "contraindications": "prior initiating testosterone gel , confirm diagnosis hypogonadism ensuring serum testosterone concentrations measured morning least 2 separate days serum testosterone concentrations normal range .",
    "warningsAndPrecautions": "testosterone topical gel supplied 60 g canisters metered dose pump delivers 10 mg testosterone , usp per complete pump actuation . metered dose pump capable dispensing 120 metered pump actuations . one ( 1 ) pump actuation dispenses 0.5 g gel . testosterone topical gel available packages 1 canister ( ndc 0591-2363-60 ) . store 20o 25oc ( 68o 77of ) [ usp controlled room temperature ] . freeze . used testosterone topical gel canisters discarded household trash manner prevents accidental application ingestion children pets .",
    "adverseReactions": "testosterone gel contraindicated men carcinoma breast known suspected carcinoma prostate [ ( 5.1 ) ( 6.1 ) ] . testosterone gel contraindicated women pregnant . testosterone cause virilization female fetus administered pregnant woman [ ( 8.1 , 8.2 ) ] .",
    "indications_original": "Testosterone topical gel is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone: \n                  \n                     Primary hypogonadism (congenital or acquired) \u2013 testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter\u2019s syndrome, chemotherapy, or toxic damage from alcohol, heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle stimulating hormone [FSH] and luteinizing hormone [LH]) above the normal range. \n                     Hypogonadotropic hypogonadism (congenital or acquired) \u2013 gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low serum testosterone concentrations but have gonadotropins in the normal or low range. \n                  \n                  \n                     \u00a0\u00a0\u00a0 Limitations of Use\n                  \n                  \n                     Safety and efficacy of testosterone topical gel in men with \u201cage-related hypogonadism\u201d (also referred to as \u201clate-onset hypogonadism\u201d) have not been established.\n                     Safety and efficacy of testosterone topical gel in males less than 18 years old have not been established [see Use in Specific Populations (8.4)].",
    "contraindications_original": "Prior to initiating testosterone gel, confirm the diagnosis of hypogonadism by ensuring that serum testosterone concentrations have been measured in the morning on at least 2 separate days and that these serum testosterone concentrations are below the normal range.",
    "warningsAndPrecautions_original": "Testosterone Topical Gel is supplied in 60 g canisters with a metered dose pump that delivers 10 mg of testosterone, USP per complete pump actuation. The metered dose pump is capable of dispensing 120 metered pump actuations. One (1) pump actuation dispenses 0.5 g of gel. \n                  Testosterone Topical Gel is available in packages of 1 canister (NDC 0591-2363-60).\n                  Store at 20o to 25oC (68o to 77oF) [See USP Controlled Room Temperature]. Do Not Freeze.\n                  Used Testosterone Topical Gel canisters should be discarded in household trash in a manner that prevents accidental application or ingestion by children or pets.",
    "adverseReactions_original": "Testosterone gel is contraindicated in men with carcinoma of the breast or known or suspected carcinoma of the prostate [see Warnings and Precautions (5.1) and Adverse Reactions (6.1)]. \n                     \n                     Testosterone gel is contraindicated in women who are pregnant. Testosterone can cause virilization of the female fetus when administered to a pregnant woman [see Use in Specific Populations (8.1, 8.2)]."
}